Skip to content
OpenCapital
Get started

Tango Therapeutics TNGX Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

Exelixis logo
ExelixisEXEL
——
Lantheus Holdings logo
Lantheus HoldingsLNTH
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Guardant Health logo
Guardant HealthGH
——
BillionToOne, Inc. logo
BillionToOne, Inc. BLLN
——

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Tango Therapeutics (TNGX) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $24.1M in Q1 2026.
How has Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number increased by 1.2% year-over-year, from $23.81M to $24.1M.
What is the long-term trend for Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Over 4 years (2021 to 2025), Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a 21.6% compound annual growth rate (CAGR), from $9.37M to $20.47M.